Merrimack Pharmaceuticals Stock Profit Margin
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Profit Margin Analysis
Merrimack Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Merrimack Pharmaceuticals has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Merrimack Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Merrimack Fundamentals
| Return On Equity | -0.0112 | |||
| Return On Asset | -0.0107 | |||
| Current Valuation | (20.36 M) | |||
| Shares Outstanding | 14.79 M | |||
| Shares Owned By Insiders | 1.19 % | |||
| Shares Owned By Institutions | 62.97 % | |||
| Number Of Shares Shorted | 842.49 K | |||
| Price To Earning | 65.70 X | |||
| Price To Book | 11.38 X | |||
| Gross Profit | (9.1 M) | |||
| EBITDA | (2.18 M) | |||
| Net Income | (1.18 M) | |||
| Cash And Equivalents | 13.36 M | |||
| Cash Per Share | 1.00 X | |||
| Debt To Equity | 33.90 % | |||
| Current Ratio | 31.85 X | |||
| Book Value Per Share | 15.25 X | |||
| Cash Flow From Operations | (1.52 M) | |||
| Short Ratio | 8.65 X | |||
| Earnings Per Share | (0.09) X | |||
| Price To Earnings To Growth | 0.07 X | |||
| Target Price | 4.0 | |||
| Beta | 1.42 | |||
| Market Capitalization | 223.75 M | |||
| Total Asset | 19.19 M | |||
| Retained Earnings | (548.82 M) | |||
| Working Capital | 18.74 M | |||
| Current Asset | 89.62 M | |||
| Current Liabilities | 88.28 M | |||
| Net Asset | 19.19 M |
About Merrimack Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |